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Abstract Clinically relevant fistula after distal pancreatic resection occurs in 5–30% of patients, prolonging recovery and
considerably increasing in-hospital stay and costs. We tested whether routine drainage of the pancreatic stump into a Roux-
en-Y limb after distal pancreatic resection decreased the incidence of fistula. From October 2001, data of all patients
undergoing pancreatic distal resection were entered in a prospective database. From June 2003 after resection, the main
pancreatic duct and the pancreatic stump were oversewn, and in addition, anastomosed into a jejunal Roux-en-Y limb by a
single-layer suture (n=23). A drain was placed near the anastomosis, and all patients received octreotide for 5–7 days
postoperatively. The volume of the drained fluid was registered daily, and concentration of amylase was measured and
recorded every other day. Patient demographics, hospital stay, pancreatic fistula incidence (≥30 ml amylase-rich fluid/day
on/after postoperative day 10), perioperative morbidity, and follow-up after discharge were compared with our initial series
of patients (treated October 2001–May 2003) who underwent oversewing only (n=20). Indications, patient demographics,
blood loss, and tolerance of an oral diet were similar. There were four (20%) pancreatic fistulas in the “oversewn” group and
none in the anastomosis group ( p<0.05). Nonsurgical morbidity, in-hospital stay, and follow-up were comparable in
both groups.
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Introduction
Pancreatic distal resection is a standardized procedure for
the resection of lesions localized to the left of the portal
vein. Despite advances in surgery during the last two
decades, leakage from the pancreatic remnant after distal
pancreatectomy presents a persistent problem.1,2 Thus, the
incidence of postoperative pancreatic fistulas varies be-
tween 5 and 30% in recent studies.3–10 Various techniques
are used for closure of the pancreatic remnant, such as
ligation of the pancreatic duct followed by closure of the
pancreatic stump with or without a serosa patch or closure
using a stapling device.6,11–14 Interestingly, even when an
identical technique was used, the reported incidence of
fistulas varies widely.15 This variation may be attributable
to differences in the definition of “pancreatic fistula” but
also to technical variabilities within groups of “identical”
stump closure and to the heterogeneity of patient
populations.16
Importantly, a recent study found that complications derived
from pancreatic fistulas after distal pancreatectomy doubled
the cost and dramatically increased health-care resource use.2
Therefore, strategies are urgently needed that aid in reduction
of the incidence of postoperative pancreatic fistulas, and thus,
may decrease direct treatment costs. A retrospective survey
found that draining the pancreatic remnant into an excluded
loop of jejunum was only used sporadically.17,18 We therefore
tested the hypothesis that routine drainage of the pancreatic
stump into a Roux-en-Y limb may decrease the fistula rate
after pancreatic distal resection.
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Patients and Methods
From October 2001, all patients undergoing pancreatic
surgery were enrolled in a prospective data registry. Patients
underwent a standardized preoperative evaluation consist-
ing of contrast-enhanced abdominal computed tomography
or magnetic resonance imaging. In selected patients,
endoscopic retrograde cholangio- and pancreatography
was performed. In patients in whom cancer was suspected,
resection was performed in the absence of hematogenous
metastases and when no gross retroperitoneal neoplastic or
complex vascular infiltration was evident. Surgery con-
sisted of an en-bloc pancreatic left resection, together with
the spleen and the adjacent lymphatic tissue in all these
patients. The extension of the cancer into the body of the
pancreas determined the amount of tissue that was resected.
In patients with chronic pancreatitis, the indications for
surgery were intractable pain, alteration of the left-sided
pancreas (e.g., pseudocysts), duct stenosis, pancreatic
stones, or suspicion of cancer. In these patients, the spleen
was conserved whenever technically feasible.
From October 2001 to May 2003, stump closure for
pancreatic distal resection was accomplished by closing the
pancreatic duct with interrupted prolene sutures followed
by oversewing the pancreatic stump, cut in a fish-tail-like
fashion, with a second layer of interrupted sutures using a
resorbable, atraumatic suture material (PDS, Ethicon,
Switzerland).
From June 2003, a modification was applied consisting
of suturing the pancreatic stump as described above
followed by an end-to-side pancreatico-jejunostomy into a
retrocolic Roux-en-Y limb with a length of at least 30 cm.
The jejunum was opened slightly smaller than the diameter
of the pancreas, and the anastomosis was performed in a
capsule-to-mucosa fashion using a single layer resorbable,
monofilament suture with interrupted stitches (PDS, Ethicon,
Switzerland). A drain was placed near the anastomosis in all
patients, and octreotide was administered for 5–7 days
postoperatively (3×0.2 mg s.c. daily). All patients received,
perioperatively, a single-dose antibiotic prophylaxis (amox-
icillin and clavulanic acid, GlaxoSmithKline, Switzerland).
Empiric antibiotic treatment was continued after surgery in
patients with manifest infections until resistance probes were
received or the clinical presentation ameliorated.
Postoperatively, patients were cared for in the intensive
or intermediate care unit as needed. Fluid was given
intravenously, and patients were allowed to drink fluids
depending on the operative procedure and clinical presen-
tation. Solid foods were administered according to
gastrointestinal (GI) function using a stepwise dietary
regimen. Abdominal drainage volume was registered daily,
and the amylase concentration of drained fluid was
measured and recorded every other day. Patient demo-
graphics, duration of hospital stay, incidence of pancreatic
fistula, perioperative morbidity, and follow-up after dis-
charge were recorded and compared with our previous
series of patients in whom the pancreatic remnant was
oversewn only. A pancreatic fistula was defined as
secretion of at least 30 ml of amylase-rich fluid (more
than 5,000 U/l) per day on or after the tenth postoperative
day. Mortality was defined as the total in-hospital death
rate. A biliary fistula was diagnosed if bilirubin-rich fluid
was drained for more than 5 days. Bleeding was defined
as the need for more than two units of packed red blood
cells more than 24 h after operation or the need for
reoperation for bleeding.
All variables were analyzed using the Fisher’s exact test,
χ2 test, and Mann–Whitney U test, where appropriate,
using SPSS Statistical Software (Chicago, IL, USA). All
quantitative data are reported as median values and ranges.
Differences at P<0.05 were considered statistically significant.
After discharge, all patients were seen in our outpatient
clinic at least once. Thereafter, follow-up was registered
using a standardized questionnaire, and patients were
contacted by phone.
Results
A total of 44 pancreatic distal resections were performed
during the study period. One patient who underwent
emergency pancreatic distal resection because of a rupture
of the pancreas after blunt abdominal trauma was excluded
from the analysis. The remaining 43 patients were included.
A total of 23 patients underwent distal resection with a
pancreatico-jejunostomy, and 20 patients underwent stump
closure by simple suturing of the pancreatic remnant.
Demographic characteristics are summarized in Table 1
and were comparable between the two groups. The
histologic classification and the range of surgical treatments
are shown in Table 2. A neoplasm was found in 74 and
85% of patients, respectively (group “anastomosis” vs
“oversewn”). Mean operative time was 345 min after
pancreatico-jejunostomy vs 305 min after “oversewing”
only; p=0.329. Duration until solid food intake was
tolerated and duration of hospital stay (group 1: 13 days
vs group 2: 16 days; p=0.325) was comparable between
groups. Drains were removed after a mean duration of
6 days in both groups ( p=0.5).
Postoperative morbidity is listed in Table 3. After
pancreatico-jejunostomy, one patient had to be reoperated
because of intra-abdominal bleeding in the region of the
gastro-duodenal artery. Subsequently, this patient developed
an intra-abdominal abscess caused by a localized necrosis
in the pancreatic head and was treated by percutaneous
drainage (amylase concentration of the drain fluid<220 U/l).
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One patient underwent interventional drainage for a retroper-
itoneal abscess after distal pancreatectomy with a pancreatico-
jejunostomy and left nephrectomy. The amylase concentration
in the drain fluid measured less than 500 U/l. No pancreatic
fistula required an operative intervention; however, all four
patients underwent interventional drainage. A 78-year-old
female patient died from postoperative sepsis and multi-organ
failure caused by an infected central venous line. The autopsy
report revealed a vital and completely healed pancreatic
anastomosis and no signs suggesting an intra-abdominal
cause of sepsis.
Follow-up was completed in 41 patients (95%). Two
patients were lost to emigration. Median follow-up was
20 months (range 1–49), and mean survival was 33 months
(95% C.I. 29–43). No readmission occurred as a result of a
postoperative pancreatic fistula. Follow-up morbidity was
comparable between the two groups. A total of 9 patients
(29%) died because of recurrent malignant disease. Six
patients were reoperated during follow-up: one patient
underwent hepatic resection because of a recurrence of a
neuroendocrine neoplasm; one patient required colon
resection because of diverticulitis; and another patient
underwent incisional hernia repair. The other three patients
had extra-abdominal surgery. No patient required recurrent
pancreatic surgery, and no patient who underwent pancrea-
ticojejunostomy developed bowel obstruction. Fourteen
patients (32%) required insulin after pancreatic resection,
and the incidence of pancreatogenic diabetes did not differ
between the two groups. Enzyme supplementation was
prescribed in 22 patients (51%), and six patients (14%)
noted clinical signs of exocrine pancreatic insufficiency
despite enzyme supplementation. The majority of patients
could work or pursue their daily activities (75 and 66%,
respectively, for groups “anastomosis” and “oversewn”).
Discussion
A pancreatic fistula according to a recently published
classification is any measurable drainage on or after
postoperative day 3 with an amylase content of more than
Table 1 Demographics in Patients Undergoing Pancreatic Distal Resection (n=43)
Clinical Data Group 1 (n=23)
(with Pancreaticojejunostomy)
Group 2 (n=20)
(No Anastomosis)
P
Value
Age (years) 58 (22–78) 60 (18–84) 0.372
Gender:
Male 9 (39%) 8 (40%) 0.954
Female 14 (61%) 12 (60%)
ASA risk classification
I–II 14 (67%) 14 (74%) 0.736
III–IV 7 (33%) 5 (26%)
Body weight (%)a 97 (80–100) 97 (87–100) 0.417
Duration of symptoms (wk) 44 (1–468) 14 (1–200) 0.037
Diabetes mellitus 2 4 (20%) 0.398
Cardiac disease 7 (30%) 5 (25%) 0.708
COPD 2 1 0.999
Albumin<30 g/l 2 1 0.995
Creatinine>150 mmol/l 5 (22%) 2 (10%) 0.412
Quantitative variables are given as median (range). A Fisher’s exact test or a χ2 test was used for qualitative variables and a Mann–Whitney
U test for quantitative variables.
ASAAmerican Society of Anesthesiology, COPD chronic obstructive pulmonary disease
a Body weight as a percentage of pre-morbid body weight
Table 2 Histology and Additional Surgical Procedures Performed
in 43 Patients Undergoing Pancreatic Distal Resection
Operative
Procedure
Group 1 (n=23) (with
Pancreaticojejunostomy)
Group 2 (n=20)
(No Anastomosis)
Histology
Pancreatic
neoplasms
13 (57%) 14 (70%)
Other
neoplasms
4 (17%) 3 (15%)
Chronic
pancreatitis
5 (22%) 2 (10%)
Other 1 1
Procedures
Splenectomy 18 (78%) 18 (90%)
Liver resection 3 (13%) 3 (15%)
Gastric
resection
3 (13%) 2 (10%)
Colon
resection
3 (13%) 2 (10%)
Nephrectomy 3 (13%) 1
Adrenalectomy 2 2 (10%)
Necrosectomy 1 0
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three times the upper limit of serum amylase19. Three
categories were defined: biochemical fistula without clini-
cal sequelae (grade A); fistula requiring any therapeutic
intervention (grade B); and fistula with severe clinical
sequelae (grade C). Because the current study was begun in
October 2001 and data were prospectively entered into a
database, we did not use the new classification published in
2005. Retrospectively, all fistulas diagnosed in this paper
were either grade B or grade C. The definition used in this
study is the same as that used in previous analyses of our
patients20,21 and is in accordance with other published
series from high-volume centers3,22. Several different
techniques were used for the treatment of the pancreatic
stump after distal resection6,11–14,23. In a large single-center
series of 235 pancreatic distal resections performed be-
tween 1994 and 1997, the incidence of postoperative
pancreatic fistula was 5%6. Others have reported a fistula
rate of almost 30%.10 However, assessment of data from
different centers is limited because of differences in fistula
definition and patient heterogeneity, precluding unbiased
comparison of outcomes. We therefore chose to perform a
single-center study and compared results with our new
technique with those from an earlier group of patients
otherwise treated identically but without a pancreatico-
jejunal anastomosis.
Patient demographics were well comparable in our two
groups of patients despite published data from other centers
reporting changes in patient characteristics and indications
for resection over time (increase in age and more resections
for cystic lesions and fewer for chronic pancreatitis)24. In
an earlier retrospective observational survey of 113
patients, 46 were treated with an additional pancreaticoen-
teric anastomosis, and no superiority of this technique was
found.17 Adam et al. performed a pancreaticoenteric anas-
tomosis in 27 of 41 patients undergoing distal pancreatic
resection between 1994 and 2001. The anastomosis was
associated with a leak-rate of 7% (2/27) compared to 29% (4/
14) in the control group, but the difference did not reach the
level of significance because of small sample size.18 In a
prospective trial, 69 patients were randomly assigned to five
treatment groups: suturing of the pancreatic stump, suturing
and applying fibrin glue, suturing plus mesh, pancreatico-
jejunostomy, and stapler closure of the stump. The overall
fistula rate was 19%, ranging from 7 to 33%, without a
statistical advantage of one technique over the other.25
Besides technical reasons, the incidence of postoperative
pancreatic fistula may also be influenced by the use of
synthetic somatostatin analogues (octreotide, lanreotide, or
vapreotide) and the texture of the gland. Three randomized
trials evaluated the use of prophylactic octreotide in patients
undergoing pancreaticoduodenectomy and found no bene-
fit for the use of octreotide, as did a meta-analysis in
2002.22,26–28 On the other hand, four randomized, placebo-
controlled, multicenter trials reported significant decreases
in overall complication rates, and two of the four reported
significantly lowered rates of pancreatic fistula in patients
receiving prophylactic octreotide. Based on such data, our
patients all received octreotide, which is also in accordance
with a recent meta-analysis, demonstrating a reduction in the
incidence of complications with the use of synthetic
somatostatin analogs.29
Pancreatic texture and consistency were correlated with a
risk of postoperative pancreatic fistula development.30
Partial resection of a fibrotic pancreas is associated with
lower leak rates (0 to 5%) compared to resection of a soft
pancreas (20 to 25%), while the incidence of a postoper-
Table 3 Postoperative Outcome (Frequency)
Parameters Group 1 (n=23)
(with Pancreaticojejunostomy)
Group 2 (n=20)
(No Anastomosis)
P
Value
Surgical morbidity
Pancreatic fistula 0 4 (20%) 0.039
Bleeding 1 1 0.995
Intra-abdominal abscess 2a 1b 0.995
Biliary fistula 0 1c 0.465
Relaparotomy 1 0 0.995
Nonsurgical morbidityd
Cardiopulmonary 6 (26%) 3 (15%) 0.087
Renal 1 2 (10%) 0.590
Other 4 (13%) 2 (10%) 0.561
Mortality 1 0 0.995
A Fisher’s exact test or a χ2 test was used for qualitative variables and a Mann–Whitney U test for quantitative variables.
a Including the one patient requiring reoperation for bleeding in this group
b This patient also suffered from a pancreatic fistula
c Related to a liver resection that was performed together with the pancreatic left resection
d Systemic complications: cardiopulmonary, renal, sepsis, neural, others
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ative fistula in a pancreas with an intermediate consistency
is 3 to 5%22.
Reoperation, septic complications with localized ab-
scesses, and bleeding are other rare but important compli-
cations and indicators of surgical quality, having also a
major impact on health-care resource consumption and
economic outcome.2,31 In our series, there were three
abscesses. However, the amylase concentration reached
the level required for a pancreatic fistula only in the abscess
in the patient from group 2.
Because of different health-care systems, duration of
hospital stay for a given intervention in Switzerland, in
general, is greater than those reported in series from the US.
Thus, in Switzerland, many complications are diagnosed
during the initial hospital stay. Accordingly, there was no early
readmission for either postoperative fistula or for abscess or
bleeding. This outcome is in contrast to a recent paper from
the US reporting on 56 patients with distal pancreatic
resection of whom eight developed a pancreatic fistula grade
B or C. Six of these eight patients were readmitted.32
The duration of hospital stay was similar in both groups
in our study, suggesting that not only the presence or
absence of a pancreatic fistula but also other factors, such
as the cardiopulmonary or renal comorbidity that was
evenly present in both groups, had a major impact on the
duration of the hospital stay.
The additional operative effort of creating a Roux-en-Y
limb and performing an anastomosis increased the duration
of the operation only a short time, but did not reach
statistical difference most likely because of the small
number of patients studied.
Conclusion
This study may serve as an effort to evaluate Roux-en-Y
drainage of the pancreatic stump after distal pancreatic
resection. Further prospective randomized studies are
needed to finally define the role of this technique in routine
pancreatic left resection. Based on our results, a randomized
trial would need 113 patients in each treatment arm to meet
a power of 90% with a 5% two-sided significance level,
assuming that a pancreatico-jejunostomy would modify the
incidence of postoperative fistula after pancreatic distal
resection by 15%.
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